MTNB (Matinas BioPharma Holdings) Payments of Debt: $-0.01 Mil (TTM As of Mar. 2026)


MTNB Matinas BioPharma Holdings Inc MTNB
31 GF Score
Price $0.76
! 3 Warning Signs
View Full Analysis

What is Matinas BioPharma Holdings Payments of Debt?

Matinas BioPharma Holdings MTNB +20.46% 31 Payments of Debt is $-0.01 Mil as of Mar. 2026. GuruFocus rates MTNB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Matinas BioPharma Holdings's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Matinas BioPharma Holdings's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01 Mil.

Matinas BioPharma Holdings Payments of Debt Related Terms

Matinas BioPharma Holdings Payments of Debt Historical Data

* Premium members only.

The historical data trend for Matinas BioPharma Holdings's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Matinas BioPharma Holdings Payments of Debt Chart

Matinas BioPharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.02 -0.01 -0.01 -0.01

Matinas BioPharma Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 -0.01 0.00
MTNB
31GF Score
Matinas BioPharma Holdings Inc MTNB
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Matinas BioPharma Holdings Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.01 Mil mean?
Matinas BioPharma Holdings (MTNB) has a Payments of Debt of $-0.01 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Matinas BioPharma Holdings and its competitors.
Is Matinas BioPharma Holdings' Payments of Debt too high?
Matinas BioPharma Holdings' current Payments of Debt is $-0.01 Mil. Overall, Matinas BioPharma Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Matinas BioPharma Holdings' Payments of Debt compare to SXTP and ARTL?
Matinas BioPharma Holdings' Payments of Debt of $-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Matinas BioPharma Holdings and its competitors. Matinas BioPharma Holdings's current Payments of Debt is $-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Matinas BioPharma Holdings stock overvalued right now?
Matinas BioPharma Holdings (MTNB) has a current Payments of Debt of $-0.01 Mil. The current Payments of Debt is $-0.01 Mil. Matinas BioPharma Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Matinas BioPharma Holdings (MTNB), the current Payments of Debt is $-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Matinas BioPharma Holdings Business Description

Address 1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
31GF Score

Get the complete analysis for MTNB

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price